Multiple intestinal atresia (MIA) is a rare cause of bowel obstruction that is sometimes associated with a combined immunodeficiency (CID), leading to increased susceptibility to infections. The factors underlying this rare disease are poorly understood. We characterized the immunological and intestinal features of 6 unrelated MIA-CID patients. All patients displayed a profound, generalized lymphocytopenia, with few lymphocytes present in the lymph nodes. The thymus was hypoplastic and exhibited an abnormal distribution of epithelial cells. Patients also had profound disruption of the epithelial barrier along the entire gastrointestinal tract. Using linkage analysis and whole-exome sequencing, we identified 10 mutations in tetratricopeptide repeat domain–7A (TTC7A), all of which potentially abrogate TTC7A expression. Intestinal organoid cultures from patient biopsies displayed an inversion of apicobasal polarity of the epithelial cells that was normalized by pharmacological inhibition of Rho kinase. Our data indicate that TTC7A deficiency results in increased Rho kinase activity, which disrupts polarity, growth, and differentiation of intestinal epithelial cells, and which impairs immune cell homeostasis, thereby promoting MIA-CID development.

Introduction

Multiple intestinal atresia (MIA) is characterized by widespread atresia, extending from the stomach to the rectum, and homogenous calcifications in the abdominal cavity (1). Patients with MIA can develop the first symptoms of the condition in utero. In a subset of patients, MIA is associated with combined immunodeficiency (CID) (2–4). MIA-CID increases a patient’s susceptibility to a broad range of pathogens, mainly bacteria and viruses. These patients have to undergo surgical intestinal resections and derivations within the first days of life, and thus require total parenteral nutrition (TPN) as a consequence of short bowel syndrome. The patients also develop hepatic cholestasis, cirrhosis, and, ultimately, chronic hepatic failure, which can be cured by liver and small-bowel transplantation. Hematopoietic stem cell transplantation can be combined, with a view to curing the CID (4, 5). The disease mechanism for MIA-CID has not been established. Given the rarity of this condition, detailed clinical and pathological descriptions are scarce. Here, we describe clinical, immunological, and pathological data from 6 patients from 6 unrelated pedigrees as well as the inherited etiology of MIA-CID in relation to severe mutations in the gene tetratricopeptide repeat domain–7A (TTC7A). Our genetic findings confirmed 2 recent reports describing 2 TTC7A mutations observed in MIA patients (6, 7). However, no functional data on TTC7A deficiency consequences in the gut were previously reported (6, 7). We therefore performed immunohistochemical staining of patients’ gut biopsies and analysis of gut-organoid cultures grown from intestinal biopsies, which provided insights into the intestinal disease and its relationship with the RhoA signaling pathway.

Results

6 patients from 6 distinct pedigrees were diagnosed with MIA prenatally or at birth after observation of multiple gastrointestinal defects, including a pyloric diaphragm and intestinal atresia (see Methods). These defects required surgical resections in the first months of life and subsequent TPN. 5 of the patients died between 8 months and 4 years of age. At the completion of the present study, patient C3 (aged 8 years) was alive and recently developed mild palmoplantar pachyderma.

Immunological data. With the exception of F3, all patients displayed early-onset, profound, generalized T cell lymphopenia and milder NK and B cell lymphopenia (Figure 1A and Table 1). Accordingly, the T cell proliferation capacity in response to mitogens, when tested, was poor. Serum IgG, IgA, and IgM levels were very
Figure 1
Immunological characteristics of MIA-CID patients. (A) Circulating blood cell counts. Shown are lymphocyte, monocyte, and neutrophil counts as well as total CD3+, CD4+, and CD8+ T cell counts. (B) Thymus pathology. H&E staining (top) revealed poor corticomedullary demarcation and a paucity of lymphocytes and Hassall's bodies in A4 versus a control subject. Also shown is immunohistochemical staining of CD3, CD8, and CD4 as well as CK5 and CK8 staining for medullary (m) and cortical (c) thymic epithelial cells, respectively. (C) Mediastinal lymph node. H&E staining and immunohistochemical staining for CD20, CD3, and CD68 in a control subject and in E3 after autopsy. Original magnification, ×50 (B), ×400 (B, enlarged H&E views), ×200 (C, H&E), ×100 (C, immunostaining).
low, whereas IgE levels were elevated in the 2 cases tested. Thus, MIA-CID was a common feature of the 6 patients, as previously reported for other cases (8). A postmortem pathology study revealed hypoplastic thymuses in D3 and E3 (respectively, one-tenth and one-third of the thymus size of age-matched controls). In A4, partial corticomedullary delineation and low CD3+ T lymphocyte cellularity were observed (Figure 1B). Cytokeratin 5 (CK5) and CK8 (markers for medullary and cortical epithelial cells, respectively) were detected in control subjects and A4; however, the CK5+ cells were abnormally distributed throughout the patient’s thymic cortex (Figure 1B). Autopsy data on E3 showed that the mediastinal lymph nodes and mesenteric lymph nodes contained few lymphoid cells; small, dispersed B follicles; and few T cells in the paracortex (Figure 1C and data not shown). There was a polymorphous inflammatory infiltrate rich in eosinophils and macrophages, as revealed by H&E and CD68 staining, respectively (Figure 1C).

**TTC7A mutations are associated with MIA-CID.** Based on the hypothesis that the MIA-CID has autosomal-recessive inheritance, we performed genome-wide linkage analysis by homozygosity mapping on families A, B, and C as well as whole-exome sequencing on A9, B3, C3, E3, and F3 (Figure 2A). Linkage analysis revealed a common 4-Mb region located on chromosome 2 (p21) (bp position, g.43,347,681–g.47,320,846, hg19) and a common 7-Mb region on chromosome 10 (bp position, g.17,038,509–g.24,566,092). Both regions had a logarithm of odds score of 1.95. No candidate genes were identified in the common region on chromosome 10. In contrast, whole-exome sequencing of the common region on chromosome 2 identified a homozygous, nonsynonymous variant in TTC7A in B3 and C3. Sanger sequencing of TTC7A's coding exons confirmed the mutations identified in B3 and C3 and identified other mutations or deletions in the 4 remaining patients, the parents, and the siblings (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI71471).
Since exon 2 could not be amplified in samples from A9, sequencing of the cDNA from each of the patient’s parents was performed, which identified a total deletion of exons 2 and 3 in the mother (A1) and exon 2 in the father (A2) (Supplemental Figure 1). The genetic anomalies identified in TTC7A in the 6 patients are summarized in Figure 2B. D3 inherited a missense mutation in exon 14 from her mother, which led to a serine-to-leucine substitution at position 539 (Supplemental Figure 1). The serine at position 539 in the human sequence is highly conserved, and the serine-to-leucine substitution is predicted to be “probably damaging” by PolyPhen2, “deleterious” by SIFT, and “disease causing” by MutationTaster. D3’s paternal mutation was not detectable by exon sequencing of the patient’s DNA. Sequencing of cDNA obtained from her father (D2) highlighted a heterozygous 4-bp deletion in exon 11 associated with exon 12 deletion, predicting premature stop codon (Supplemental Figure 1). One of the heterozygous mutations identified in F3, inherited from his father (F2), is located within intron 12 (g.47102777 T>A) at some distance from a splice site. Sequencing of the father’s cDNA showed a heterozygous splicing defect that causes deletion of exon 12 (Supplemental Figure 1). In the other patients, the identified mutations either create a nonsense codon directly or create a subsequent nonsense codon indirectly via a frameshift in the TTC7A sequence. The identified point mutations and deletions were neither found in in-house exome sequencing data nor in any of the publically available databases (including the dbSNP129 and 1,000 Genomes datasets). Heterozygous individuals were asymptomatic.

**Immunopathology of the gut.** Immunochemistry revealed disruption of the architecture of the mucosa alone, from the stomach to the colon (Figure 3A). The epithelium was pseudostratified, with hyperchromatic nuclei, signs of apoptosis, and partial or total destruction of the glands. These abnormalities were detectable from birth onward. In the small intestine, villi were scarce or absent. The cellular infiltrate within the lamina propria consisted mainly of eosinophils and macrophages. The lymphocyte population was similar to that seen in controls, as shown by staining for CD3 and CD20 (Figure 3B and data not shown). A few lymphoid follicles were present. In the proximal small intestine, the number of mucus-secreting cells and lysozyme-containing cells was normal (data not shown). In patient biopsies, Ki67+ proliferating epithelial cells were detected only in a few crypts (Figure 3B). CK20 staining was detected at the surface of epithelium and partially shed in the gut lumen. It was additionally observed in the glands (Figure 3B), highlighting the epithelium’s abnormal, pseudostratified structure. Villin expression was low, with a very weak signal visible on the luminal side of the epithelium and within a few epithelial vacuoles, instead of at the apex (Figure 3B). Alkaline phosphatase (AP) activity was totally disrupted in patients relative to controls (Figure 3B), indicative of defective apical pole function.
in the epithelium. Taken together, these data highlight the profound disruption of the epithelial architecture in MIA-CID, with loss of apical pole function associated with infiltration of eosinophils and macrophages in the mucosa.

**Intestinal organoids from MIA-CID patients show disrupted apicobasal polarity.** The clinical and pathological findings in MIA-CID patients suggested that TTC7A had a prime role in intestinal epithelial cells. We thus established 3-dimensional organoid cultures as a model for self-renewal and differentiation (9, 10). Small intestine biopsies from C3 and E3 showed efficient initial outgrowth (Supplemental Figure 2), suggestive of the presence of Lgr5 stem cells in atretic regions. However, although control organoids could be expanded over many months, patient organoids deteriorated after several passages; only those of C3 could be grown long enough to be further analyzed. These patient organoids displayed a disturbed epithelial architecture, lacked a central lumen (villus domain) and budding processes (crypts), and formed dense cellular aggregates (Figure 4A). Coimmunofluorescence analysis of Ki67 and CK20 expression revealed loss of proliferation and gain of cytodifferentiation, respectively (Figure 4B), with a mild excess of cell death (as shown by caspase-3 immunostaining; data not shown), which demonstrated TTC7A’s prime role in gut epithelial homeostasis.

**ROCK inhibition reverses epithelial abnormalities in TTC7A-deficient intestinal epithelial cells.** We previously reported that pharmacologic inhibition of Rho kinase (ROCK) with Y-27632 was required to avoid cell death in isolated intestinal stem cells after the loss of cell-cell contacts (9). We hypothesized that addition of Y-27632 might also support survival of TTC7A-deficient organoids after passaging, a process that involves mechanical shearing and reseeding. Indeed, continuous addition of Y-27632 facilitated the expansion of patient cultures (Figure 4, A–C), but was not essential for control cultures. In patient-derived organoids, ROCK inhibition caused formation of large, cystic structures with renewed Ki67 expression and reduced CK20 expression (Figure 4, A and B, and Supplemental Videos 1 and 2). Western blot analysis showed that untreated patient-derived organoids contained abnormally high levels of phospho–ezrin/radixin/moesin (P-ERM) and phosphomyosin light chain (P-MLC), both of which are downstream targets

---

**Figure 3**

Immunohistologic studies of the digestive tract of MIA-CID patients. (A) Pathology studies of the stomach, intestine, and colon. H&E staining of the stomach (antrum) in a control subject (12 years old) and A9 (6 months old). Asterisks denote pseudostratified epithelium; arrow denotes apoptosis in glands. Compared with the proximal small intestine in a control subject (7 days old), that of E3 (2 days old) showed cysts and protrusions of multilayered epithelial cells as well as infiltration with eosinophils. Colon was stained with H&E in a control subject (12 years old) and A9 (6 months old). (B) Immunochemical staining was performed to detect markers for epithelial differentiation as well as AP — as a marker for intestinal epithelium function — in the proximal small intestine in a control subject (1 day old) and patient (2 days old). Staining showed lamina propria infiltration by T cells (CD3) and macrophages (CD68) and Ki67-positive, proliferating epithelial cells as well as expression of CK20, villin, and AP. Original magnification, ×200 (A, stomach and colon, and B), ×50 (A, small intestine), ×400 (A, small intestine, enlarged view).
of ROCK (11), whereas expression of both ROCK and Rho were similar to control values. After treatment with Y-27632, P-ERM and P-MLC expression returned to control levels (Figure 4D).

The MIA-CID patients displayed pseudostratified gut epithelium and disturbed nuclear positioning both in vivo and in vitro. These features are suggestive of defects in apicobasal polarity. It is known that elevated ROCK activity and MLC phosphorylation disrupt epithelial polarity in cell-based models (12). We therefore decided to study polarity markers in organoids after withdrawal of Y-27632. Basolateral expression of \( \alpha_6 \) integrin and \( \beta_6 \) integrin was partially lost; instead, these proteins accumulated at cell-cell junctions inside cell aggregates (Figure 4E and data not shown). The apical brush border actin, which faced the lumen in controls, was deposited at the periphery in patient-derived organoids. The tight junction protein ZO-1, which is normally found below the apical brush border, was detected ectopically (i.e., on both sides of the epithelium; Figure 4E). Culture with Y-27632 restored polarity and suppressed differentiation in patient cultures, but could not rescue abnormal nuclear positioning (blue; DAPI). (C) Growth profile for control- and patient-derived organoids in the presence or absence of Y-27632. Mean organoid number after passaging of 3 independent wells each. Error bars denote SEM. **\( P < 0.01 \), ***\( P < 0.0001 \), t test. (D) Western blot analysis of patient-derived organoids showed increased ROCK activity. Membranes were probed with anti-ROCK, anti-P-ERM, anti-Rho, and anti-P-MLC. Actin was used as a loading control. (E) Analysis of cell polarization by immunostaining of \( \alpha_6 \) integrin (green) and F-actin (red) in the apical brush border and of the tight junction marker ZO-1 (green). Control- and patient-derived organoids were cultured in the absence of Y-27632. Nuclei were stained with DAPI (blue). Scale bars: 100 \( \mu \)m.

Together, our present findings are indicative of an association between increased ROCK activity and spontaneous differentiation and defective apicobasal polarity in patients with TTC7A mutations. *TTC7A-dependent ROCK activation in nonepithelial cells and complementation of the defect.* We next looked at whether the functional link between TTC7A and the RhoA pathway in the intestinal epithelium could be detected in other differentiated cell types, as TTC7A is expressed in multiple tissues (13). Given the profound lymphopenia displayed by MIA-CID patients, lymphocytes could not be evaluated. We analyzed fibroblast cell lines derived from C3 and E3 skin biopsy. Western blotting revealed substantially elevated phosphorylation of P-ERM and P-MLC in cell lysates of patient- versus control-derived fibroblasts (Figure 5G). As observed in intestinal gut epithelial cells, phosphorylation of these proteins was normalized when the patient-derived fibroblasts were incubated in the presence of Y-27632. In addition, expression of a wild-type TTC7A construct (referred to herein as WT-TTC7A) in patient-derived
fibroblasts was sufficient to rescue both P-ERM and P-MLC expression to near-control levels (Figure 5H), demonstrating a direct role of TTC7A in regulation of the ROCK pathway. Finally, the patient-derived fibroblasts displayed an increased adhesion and proliferation capacity compared with controls that was reduced by WT-TTC7A expression (Figure 5I).

**Discussion**

We found that biallelic mutations in TTC7A were responsible for an autosomal-recessive inherited MIA-CID syndrome in 6 patients from unrelated families. All but 1 of the identified genetic anomalies lead to nonsense codons or are predicted to cause a frameshift mutation. The only identified heterozygous missense mutation...
research article

Figure 6
ROCK targets responsible for cytoskeleton assembly. Modulation of cytoskeleton assembly is required for the coordination of cell adhesion, polarization, and migration. The active form of RhoA (RhoA-GTP) activates ROCK and interacts with the integrin intracellular signaling pathway. RhoA also modulates cytoskeleton reorganization via focal adhesion kinase (FAK) activation and front-rear polarity via phosphorylation of phosphatase and tensin homolog (PTEN). Phosphorylation of ROCK's downstream effector MLC is required for the assembly of actomyosin complexes. ROCK downregulates the MLC phosphatase (MLCPase), resulting in an increase in phosphorylated MLC. Cell contraction, actin organization, stress fiber formation, and focal adhesions, which confer contractility and migration properties to the cell. Phosphorylation of ROCK's downstream effector ERM has a role in microvilli formation. Phosphorylated Lim domain kinase (Lim-K) phosphorylates and thus deactivates the actin-depolymerizing protein cofilin. Y-27632 blocks Rho-induced actomyosin activation. These data support a role for TTC7A in the downregulation of ROCK activity. Activation and inactivation are shown as arrowheads and blunted lines, respectively. MLCK, myosin light chain kinase; NHE1, Na+/H+ exchange protein.

leads to a serine-to-leucine transition at residue 539; this mutation is predicted to be deleterious by 3 different software tools. The mutation is located in the tetratricopeptide repeat 5 (TPRS) domain, 1 of 2 containing a triple TPR, which is thought to be the minimal functional unit for this motif (14). The TPR-containing protein TTC7A does not have a known function. TPR motifs are protein-protein interaction modules present in numerous functionally different proteins (15). The motifs facilitate specific interactions with one or more partner proteins. Most TPR-containing proteins are involved in complex multiprotein functions in chaperoning, cell cycling, transcription, and protein transport (16, 17). In concert with 2 recent reports on different mutations in TTC7A in patients with MIA (6, 7), our present findings establish a critical role for TTC7A in both the gut and the immune system.

We showed that TTC7A deficiency in the patients described herein affected the immune system and rapidly led to lymphocytopenia, particularly for peripheral T lymphocytes. T cell lymphopenia in MIA-CID might be related to a role for TTC7A in lymphocyte differentiation, proliferation, and survival. The low number of peripheral lymphocytes in these patients precluded further analysis. However, the characteristics of the immunodeficiency associated with a hypomorphic mutation in TTC7A (R. Lemoine, unpublished observations) suggest that TTC7A acts to maintain lymphocyte homeostasis by regulating functions such as cell adhesion, proliferation, and migration. Furthermore, we showed that patients with MIA-CID present a hypoplastic thymus with low lymphocyte cellularity and ectopic distribution of Ck5 in the cortex. Severe lymphoid depletion in the thymus of an MIA-CID patient was also recently reported (7). Given that TTC7A expression occurs in many tissues, including the thymic epithelium, we cannot rule out the possibility that defective TTC7A function in the thymic epithelium may also contribute to T cell lymphopenia.

A lack of TTC7A led to dramatic disruption of the gut mucosal architecture in the patients, extending from the stomach to the colon. There was no evidence of a blockade in epithelial cell differentiation. The main anomalies were the presence of many disorganized, pseudosтратified cell structures; a low number of villi; and high levels of cell apoptosis. Our study of gut organoids established from 2 MIA-CID patients highlighted TTC7A’s critical role in regulating the balance between growth and differentiation of intestinal epithelial cells. Furthermore, this gut organoid analysis established that TTC7A has a decisive role in the apicobasal polarization of epithelial cells by regulating the RhoA signaling pathway. Apicobasal polarity is regulated through the cytoskeletal proteins (including the integrins) that mediate cell-matrix and cell-cell adhesion (18). The establishment and maintenance of multicellular epithelial tissues require each cell to be polarized with the correct orientation. This is also true for formation of the central lumen. It was previously shown that blockade of β1 integrin in Madin-Darby canine kidney cells inverts the cells’ apicobasal polarity by activating the RhoA signaling pathway and that the latter phenotype can be reversed by treatment with the ROCK inhibitor Y-27632 (12). Similarly, gut tube formation during embryogenesis was shown to depend on ROCK activity (19). Here, we demonstrated that TTC7A is a key player in this signaling pathway and is necessary for coordinated epithelial cell polarity, growth, and differentiation. TTC7A downregulates the activity of ROCK and its effector targets, ERM and myosin II (20, 21). Like other ROCK targets, ERM and myosin II are cytoskeleton regulators that modulate both F-actin and stress fiber contractility as well as integrin activity (Figure 6). These changes influence cell shape, polarization, and motility (22). The pleiotropic role of the RhoA signaling pathway in immune cells is also well established. Myosin II activity was previously shown to reduce T cell motility and favor their arrest upon TCR activation, a necessary step in synapse formation (23). Thus, by interacting with several cytoskeleton regulators, TTC7A-dependent ROCK activity interferes with key cellular functions in epithelial and lymphocyte homeostasis. We suggest that these cellular changes account for the phenotype displayed by MIA-CID patients. How TTC7A regulates the ROCK pathway remains to be determined. The TPR proteins’ ability to participate in several simultaneous interactions suggests that TTC7A could interact with one or more of the effectors or regulators in the ROCK pathway.

In conclusion, our present findings pave the way to better understanding of MIA-CID and highlight a previously unexpected, common mechanism regulating the lymphocyte and epithelial cell differentiation in the gastrointestinal tract and, potentially, the thymus. Since MIA has not always been associated with a CID phenotype, it remains to be seen whether CID was not recognized, given the rapid lethal nature of the disorder, or whether isolated MIA results from specific TTC7A mutations, or even other genetic defects affecting the ROCK pathway.
Methods
MIA-CID patients. A9 (female) was born to nonconsanguineous parents of mixed European descent. Her 3 older brothers all had the same phenotype and had died in the first months of life (due to infections and post-transfusion graft–versus-host disease, as previously reported; ref. 8). At birth, A9 was diagnosed with several gastrointestinal defects: prepyloric diaphragm, micro–small intestine, microcolon, and colic atresia. At day 3 after birth, she underwent diaphragm resection, hemicolecotomy, and a double ileostomy. At 18 months of age, she underwent further surgery (cholecystectomy, pyloroplasty, and gastrectomy). TPN was initiated at 7 months of age. A9 had a chronic subocclusion and developed progressive hepatic cholestasis and cirrhosis. She displayed progressive, generalized, profound lymphopenia and panhypogammaglobulinemia, which required Ig replacement therapy and anti-infective prophylaxis. A thymus line could not be visualized on a chest X-ray at 20 months of age. A9 died at 2.5 years of age due to sepsis.

B3 (female) was born in Saudi Arabia to consanguineous parents who had then emigrated to the United Kingdom. A prenatal ultrasound diagnosis of MIA was confirmed at birth and prompted initiation of TPN. During intestinal surgery at 5 weeks of age, a duodenal membrane was found, and more than 50 cm of small intestine (including the ileocecal region) was resected. B3 underwent further intestinal resection at 2 months of age. At 7 weeks of age, she developed sepsis and transient hyperbilirubinemia. An episode of Klebsiella sepsis occurred at 3 months of age. B3 was transferred to the United Kingdom for medical management at 5 months of age. She was found to have profound, generalized lymphopenia. She received a hematopoietic stem cell transplant (from an HLA 5/6-matched unrelated cord blood donor) at 8 months of age, but developed Pseudomonas pneumonia and severe sepsis, which led to death from a pulmonary hemorrhage at 9 months of age.

C3 (male) was born in France to parents from 2 villages a few miles apart in Sri Lanka. A prenatal diagnosis of intestinal atresia was confirmed at birth. TPN was initiated, but the patient developed progressive hepatic cholestasis and cirrhosis. He displayed rapidly progressive, generalized, profound lymphopenia and severe panhypogammaglobulinemia, which required Ig replacement therapy and anti-infective prophylaxis. C3 did not undergo organ transplantation, because surgery was contraindicated by severe bronchiectasis. From the age of 4 years onward, he developed progressive skin abnormalities with mild pachyderma on both hands and feet.

D3 (female) was born in Norway to nonconsanguineous parents from the same city. She had an enlarged abdomen at birth and was transferred for surgery the next day. D3 presented with multiple atresias — particularly colonic atresia and stenosis — that were removed, and she received TPN for the rest of her life. Postoperatively, she developed a severe infection that was treated with broad-spectrum antibiotics for several weeks. At that point, lymphocytopenia and panhypogammaglobulinemia was detected. In biopsies from both the small intestine and sigmoid, cytomegalovirus was found by immunohistochemistry and PCR. D3 received antibiotic prophylaxis and Ig substitution; however, her clinical condition gradually deteriorated, and she died at 8 months of age from pneumonia with sepsis. Klebsiella pneumonia was found in blood culture and Pneumocystis proventi in the lungs at autopsy.

E3 (female) was born in Belgium to nonconsanguineous parents of mixed European descent. She underwent multiple gastrointestinal tract operations, starting in the first few days of life (intestinal resection, duodenostomy, and ileostomy). She suffered from multiple atresia of the proximal digestive tract, with pre- and postduodenal atretic segments. The duodenal loop was massively dilated (extending from the antpyloric region to the duodenojejunal junction [the angle of Treitz]), and a second atresia was found within the duodenojejunal segment. At 10 months of age, E3 developed rapidly progressive, profound, generalized lymphopenia and severe panhypogammaglobu-
(Dako) containing biotinylated goat anti-mouse and anti-rabbit secondary antibody, streptavidin-labeled HRP, and DAB.

**Protein blotting.** Intestinal organoids and SV40-immortalized fibroblasts were lysed in radioimmunoprecipitation/glycerol buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, and 1% sodium deoxocholate) supplemented with protease inhibitors (Roche) and phosphatase inhibitors (Sigma-Aldrich). Cell extracts were separated by SDS-PAGE, blotted, and then stained with the specific antibodies anti-ROCK, anti-P-ERM, and anti-P-MLC (Cell Signaling). After staining with a HRP-conjugated secondary antibody, the immunoblot was developed with an enhanced chemiluminescence detection kit (GE Healthcare Life Sciences).

**Rescue experiments.** Full-length TTC7A cDNA was subcloned into the EcoR1 and BamH1 restriction sites of the pEGFP-C1 plasmid (Clontech) according to the manufacturer’s instructions. Western blotting was performed 24 hours after transfection.

**Cell adhesion assays using xCELLigence technology.** For adhesion and proliferation assays, 3,000 fibroblasts derived from C3, E3, and control skin biopsies were transiently transfected with WT-TTC7A. After 24 hours, cells were added to E-plate wells containing 50 μl medium, incubated for 20 minutes at room temperature, and then cultured at 37°C in 5% CO2. Cell adhesion was monitored every 5 minutes for up to 20 hours. The electrical impedance was measured as a cell index by the xCELLigence system’s integrated software.

**Statistics.** Analyses were performed with PRISM software (version 4 for Macintosh, GraphPad Inc.). Statistical hypotheses were tested using a 2-tailed Student’s t test. A value less than 0.01 was considered significant.

**Acknowledgments.** We thank Capucine Picard for the immunological study of C3 and Naziba Khen-Dunlop and Joseph Amirandoum for performing intestinal biopsies for organoids. We thank Anne Servais, Vincent Delorme, and C. Mulder for providing biological samples; J. Viala and M. Lecompte-Houcke for providing useful information on patients; and Cécile Masson for participation in exome analysis. We thank all technicians and secretarial staff from the Pathology Department of Necker Hospital, in particular Martine Hennebo, Gisèle Legall, Claire Gandon, Stéphanie Petit, Annie Postel, Nicole Mariage, and Agathe Helan, for their technical support. This research was supported by INSERM, by ANR-08-GENO-020-01, and by an advanced grant from the European Research Council (ERC, PIDImmum reference no. 249816) and the “Imagine Foundation.”

Received for publication June 7, 2013, and accepted in revised form September 26, 2013.

Address correspondence to: Geneviève de Saint Basile, INSERM U768, Hôpital Necker Enfants-Malades, 149 rue de Sévres, Paris, F-75015, France. Phone: 33.1.44.38.17.66; Fax: 33.1.42.73.06.40; E-mail: genevieve.de-saint-basile@inserm.fr.

---

**Study approval.** Clinical information and blood samples were collected from patients, relatives, and controls, all of whom had given prior informed consent to participate in the study. Genetic studies and data collection procedures were approved by the local investigational review board and the French Advisory Committee on Data Processing in Medical Research.